Kerrisdale's opinion is not shared by all and the drug is in fact being co-developed with Bristol-Myers Squibb ($BMY), who signed a deal worth as much as $975 million last March, with a $60 million upfront payment. The company has the option to license the drug and sits well with its melanoma immunotherapy Yervoy and its new checkpoint inhibitor Opdivo, with these medicines also slated to be used alongside Prostvac in future trials. Analysts at Edison Research have predicted that Prostvac could eventually achieve sales of $1.3 billion at peak (assuming a treatment price of $50,000 a year), should it gain approval. And it's not the only Big Pharma to show interest: late last year, Johnson & Johnson ($JNJ) penned a deal with the company to co-develop a HPV vaccine alongside Janssen's AdVac technology. Neither of the two companies released financial terms of the deal.